Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644418 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL21644419 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL21001865 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2NR1H2 | |
| SCHEMBL21040540 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL3965738 | 0.79 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL3965735 | 0.79 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL1475537 | 0.77 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL15476025 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL15476024 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL24351334 | 0.76 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | USP2 3182/4885SMN1; SMN2 4475/4885HPGD 285/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | USP2 3294/4885SMN1; SMN2 4277/4885HPGD 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.